Revenue
2023
2024
2025
Artiva Biotherapeutics, Inc. (ARTV)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0 | $251,000 | $32.9M |
| Research & development | $69.5M | $50.3M | $50.3M |
| Operating expenses | $89.8M | $67.5M | $64.2M |
| Operating income | −$89.8M | −$67.3M | −$30.7M |
| EBITDAderived | −$87.2M | −$64.9M | −$28.4M |
| Net income | −$83.9M | −$65.4M | −$28.7M |
| Basic EPSper diluted share | -$3.43 | -$5.81 | -$35.78 |
| Diluted EPSper diluted share | -$3.43 | -$5.81 | -$35.78 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +5Director,TenPercentOwner | BuyCommon Stock · indirect | 1.9K | $8.98 | $16.8K | 16.80M |
| Jun 25, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +5Director,TenPercentOwner | BuyCommon Stock · indirect | 31.0K | $8.88 | $275.3K | 16.79M |
| Jun 16, 2026Form 4 | Kolchinsky Peter +5Director,TenPercentOwner | BuyCommon Stock · indirect | 124.9K | $8.89 | $1.11M | 16.76M |
| Jun 15, 2026Form 4 | Kolchinsky Peter +5Director,TenPercentOwner | BuyCommon Stock · indirect | 15.4K | $8.99 | $138.6K | 16.64M |
| Jun 12, 2026Form 4 | Kolchinsky Peter +5Director,TenPercentOwner | BuyCommon Stock · indirect | 391.0K | $8.57 | $3.35M | 16.62M |